Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | QPCT | Q16769 | 3/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CDK7 | P50613 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995010 | 1.00 | NAMPT (0.53) | NAMPTCITROCK2ROCK1LTA4H | |
| SCHEMBL4008313 | 0.85 | ROCK2 (0.67) | NAMPTCITROCK2ROCK1LTA4H | |
| SCHEMBL4008855 | 0.85 | ROCK2 (0.67) | NAMPTCITROCK2ROCK1LTA4H | |
| SCHEMBL4008308 | 0.85 | ROCK2 (0.67) | NAMPTCITROCK2ROCK1LTA4H | |
| SCHEMBL26190497 | 0.80 | ROCK2 (0.53) | NAMPTROCK2ROCK1QPCT | |
| SCHEMBL13373422 | 0.79 | NAMPT (0.81) | NAMPTROCK2QPCT | |
| SCHEMBL3009022 | 0.78 | HDAC8 (0.54) | AKT1 | |
| SCHEMBL23466528 | 0.77 | KDM4E (0.57) | CITROCK2ROCK1AKT1BACE1 | |
| SCHEMBL9960184 | 0.77 | NAMPT (0.62) | NAMPTROCK2QPCT | |
| SCHEMBL23466525 | 0.77 | KDM4E (0.57) | CITROCK2ROCK1AKT1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | NAMPT 2318/4885CIT 2544/4885ROCK2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.